Literature DB >> 12860201

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

Mohammad Kavianipour1, Mario R Ehlers, Klas Malmberg, Gunnar Ronquist, Lars Ryden, Gerhard Wikström, Mark Gutniak.   

Abstract

Glucagon-like peptide-1 (7-36) amide (GLP-1) has been studied as a treatment option in diabetic patients. We investigated the effect of recombinant GLP-1 infusion on hemodynamic parameters, myocardial metabolism, and infarct size during normoxic conditions as well as during ischemia and reperfusion using an open-chest porcine heart model. In the presence of rGLP-1, interstitial levels of pyruvate and lactate decreased during ischemia and reperfusion both in ischemic and non-ischemic tissue. Moreover, rGLP-1 infusion resulted in increased plasma insulin levels and decreased blood glucose levels. Neither hemodynamic variables nor the consequent infarct size were influenced by rGLP-1 infusion. We conclude that rGLP-1 altered myocardial glucose utilization during ischemia and reperfusion. It did not exert any untoward hemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860201     DOI: 10.1016/s0196-9781(03)00108-6

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  35 in total

Review 1.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 2.  Incretin-related drug therapy in heart failure.

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 3.  Cardiovascular effects of incretin-based therapies.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2011-11-10

4.  [Cardiovascular effects of incretin-based therapies].

Authors:  M Lehrke; N Marx
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

5.  Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Authors:  Thomas Jax
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

6.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

Authors:  Que Liu; Christen Anderson; Anatoly Broyde; Clara Polizzi; Rayne Fernandez; Alain Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-16       Impact factor: 9.951

7.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Authors:  Que Liu; Lisa Adams; Anatoly Broyde; Rayne Fernandez; Alain D Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-08-03       Impact factor: 9.951

8.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

9.  Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

Authors:  Jens Kristensen; Ulrik M Mortensen; Morten Schmidt; Peter Haubjerg Nielsen; Torsten Toftegaard Nielsen; Michael Maeng
Journal:  BMC Cardiovasc Disord       Date:  2009-07-23       Impact factor: 2.298

10.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.

Authors:  Anne Gill; Byron J Hoogwerf; Jude Burger; Simon Bruce; Leigh Macconell; Ping Yan; Daniel Braun; Joseph Giaconia; James Malone
Journal:  Cardiovasc Diabetol       Date:  2010-01-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.